Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn's Disease.

Autor: Graham DY; Departments of Medicine, Molecular Virology, and Microbiology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX 77030, USA., Naser SA; Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32816, USA., Borody T; Center for Digestive Diseases, Sydney 2046, Australia., Hebzda Z; Specjalistyczne Centrum Medyczne Unimedica, 31-271 Krakow, Poland., Sarles H; Digestive Health Associates of Texas (DHAT) Research Institute, Garland, TX 75044, USA., Levenson S; Digestive Care Associates, Inc., San Carlos, CA 94070, USA., Hardi R; Department of Gastroenterology, George Washington University Medical School, Washington, DC 20052, USA., Arłukowicz T; Collegium Medicum, University of Warmia and Mazury, 10-082 Olsztyn, Poland., Svorcan P; School of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Zvezdara University Medical Center, 11000 Belgrade, Serbia., Fathi R; RedHill Biopharma, Ltd., Tel Aviv 6473921, Israel., Bibliowicz A; RedHill Biopharma, Ltd., Tel Aviv 6473921, Israel., Anderson P; RedHill Biopharma, Ltd., Tel Aviv 6473921, Israel., McLean P; RedHill Biopharma, Ltd., Tel Aviv 6473921, Israel., Fehrmann C; CEEF Solutions, Pointe-Claire, QC H9S 4L7, Canada., Harris MS; Middleburg Consultants, Takoma Park, MD 20912, USA., Zhao S; Syneos Health, Morrisville, NC 27560, USA., Kalfus IN; M2g Consulting, Inc., New York, NY 10024, USA.

Publikováno v: Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2024 Jul 25; Vol. 13 (8). Date of Electronic Publication: 2024 Jul 25.

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

Autor: Woude, C.J. van der, Stokkers, P., Bodegraven, A.A. van, Assche, G. van, Hebzda, Z., Paradowski, L., D'Haens, G., Ghosh, S., Feagan, B., Rutgeerts, P., Dijkstra, G., Jong, D.J. de, Oldenburg, B., Farhan, M., Richard, T., Dean, Y., Hommes, D.W., ICC

Publikováno v: Inflammatory Bowel Diseases, 16(10), 1708-1716
Inflammatory bowel diseases, 16(10), 1708-1716. John Wiley and Sons Inc.
Inflammatory Bowel Diseases, 16, 10, pp. 1708-16
Inflammatory Bowel Diseases, 16(10), 1708-1716. John Wiley and Sons Inc.
Inflammatory Bowel Diseases, 16(10), 1708-1716. Oxford University Press
van der Woude, C J, Stokkers, P, van Bodegraven, A A, Van Assche, G, Hebzda, Z, Paradowski, L, d'Haens, G, Ghosh, S, Feagan, B, Rutgeerts, P, Dijkstra, G, Jong, D J, Oldenburg, B, Farhan, M, Richard, T, Dean, Y & Hommes, D W 2010, ' Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease ', Inflammatory Bowel Diseases, vol. 16, no. 10, pp. 1708-1716 . https://doi.org/10.1002/ibd.21252
Inflammatory Bowel Diseases, 16, 1708-16
Inflammatory Bowel Diseases, 16(10), 1708-1716. LIPPINCOTT WILLIAMS & WILKINS

Item does not contain fulltext BACKGROUND: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fe4793401376f62fd00a7df27f7a8c4
https://doi.org/10.1002/ibd.21252

Gastric Protection by Nocloprost against Aspirin Damage in Humans Possible Role of Epidermal Growth Factor.

Autor: Konturek, S. J., Konturek, J. W., Kwiecien, N., Obtulowicz, W., Oleksy, J., Hebzda, Z., Amon, I.

Publikováno v: Scandinavian Journal of Gastroenterology; 1991, Vol. 26 Issue 3, p231-236, 6p

Effects of Protective Drugs on Gastric Alkaline Secretion in Man.

Autor: Konturek, S. J., Kwiecien, N., Obtulowicz, W., Hebzda, Z., Oleksy, J.

Publikováno v: Scandinavian Journal of Gastroenterology; 1987, Vol. 22 Issue 9, p1059-1063, 5p

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.

Autor: van der Woude CJ; Erasmus Medical Centre Rotterdam, Netherlands. c. vanderwoude@erasmusmc.nl, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, D'Haens G, Ghosh S, Feagan B, Rutgeerts P, Dijkstra G, de Jong DJ, Oldenburg B, Farhan M, Richard T, Dean Y, Hommes DW

Publikováno v: Inflammatory bowel diseases [Inflamm Bowel Dis] 2010 Oct; Vol. 16 (10), pp. 1708-16.